John,
Thanks for warning. I am organic chemist with little knowledge in biochemistry. Neuroscience is new field for me, and any comments are welcome.
Do you have stats data (note or summary of presentation) for Cerestat. Also, are they related to stroke or/and traumatic brain injury. If do, please post them or send me e-mail.
Indeed, I did not found many printed data on Cerestat (Aptiganel Hydrochloride or, by chemist, N-(naphthyl)-N'-(ethylphenyl)-N'-methylguinidine hydrochloride). Also, I am following CNSI for last year, not very long period.
It was surprise for me, how quickly Boehringer move in to P-III Cerestat clinical trials.
They(BI) are very familiar with stroke (recently they didn't have success with their own compound for stroke), and with respect to German pharmaceutical industry, I assume that Cerestat is performing better than they expected. Also, accounting research results accumulation at CNSI (patents and publicized articles in prominent Journals), it was IMO good bay (I bought at 9, and recently at 11).
Considering recent REGN story ( which I witness in my own skin), momentum(not progressive) trend in biotechnology comp. stacks, other competitors for stroke, I will be careful.
Miljenko |
